TW200950777A - Abrogating proinflammatory cytokine production during oncolytic reovirus therapy - Google Patents

Abrogating proinflammatory cytokine production during oncolytic reovirus therapy Download PDF

Info

Publication number
TW200950777A
TW200950777A TW098117657A TW98117657A TW200950777A TW 200950777 A TW200950777 A TW 200950777A TW 098117657 A TW098117657 A TW 098117657A TW 98117657 A TW98117657 A TW 98117657A TW 200950777 A TW200950777 A TW 200950777A
Authority
TW
Taiwan
Prior art keywords
leu
ser
ala
val
asp
Prior art date
Application number
TW098117657A
Other languages
English (en)
Chinese (zh)
Inventor
Matthew C Coffey
Bradley G Thompson
Hardev Pandha
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of TW200950777A publication Critical patent/TW200950777A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
TW098117657A 2008-05-27 2009-05-27 Abrogating proinflammatory cytokine production during oncolytic reovirus therapy TW200950777A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5629208P 2008-05-27 2008-05-27
US11379108P 2008-11-12 2008-11-12

Publications (1)

Publication Number Publication Date
TW200950777A true TW200950777A (en) 2009-12-16

Family

ID=41376509

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098117657A TW200950777A (en) 2008-05-27 2009-05-27 Abrogating proinflammatory cytokine production during oncolytic reovirus therapy

Country Status (11)

Country Link
US (2) US8470312B2 (fr)
EP (1) EP2296679A4 (fr)
JP (1) JP2011520994A (fr)
CN (1) CN102065873A (fr)
AU (1) AU2009253683B2 (fr)
CA (1) CA2723587C (fr)
IL (1) IL208380A (fr)
MX (1) MX2010012857A (fr)
TW (1) TW200950777A (fr)
WO (1) WO2009143611A1 (fr)
ZA (1) ZA201008017B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2952583A1 (fr) 2007-03-12 2015-12-09 Oncolytics Biotech Inc. Rétrovirus ayant des séquences modifiées
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
WO2017141942A1 (fr) * 2016-02-16 2017-08-24 国立大学法人大阪大学 Composition médicinale pour le traitement de la fibrose

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
EP1905304A3 (fr) * 1997-10-09 2008-08-13 Wellstat Biologics Corporation Traitement de tumeurs avec des virus
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
DK2189162T3 (da) * 2000-11-09 2014-02-03 Oncolytics Biotech Inc Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
DK2253701T3 (da) 2001-03-16 2014-10-20 Oncolytics Biotech Inc Fremgangsmåde til ekstraktion af en virus fra en cellekultur
MXPA05007382A (es) * 2003-01-10 2005-11-23 Threshold Pharmaceuticals Inc Tratamiento de cancer con 2-desoxiglucosa.
US20070190032A1 (en) * 2006-02-13 2007-08-16 Oncolytics Biotech Inc. Use of Local Immune Suppression to Enhance Oncolytic Viral Therapy
US8293498B2 (en) * 2006-12-20 2012-10-23 Vanderbilt University System for generation of viable reovirus from cloned cDNA
EP2952583A1 (fr) * 2007-03-12 2015-12-09 Oncolytics Biotech Inc. Rétrovirus ayant des séquences modifiées
AR066649A1 (es) 2007-05-21 2009-09-02 Oncolytics Biotech Inc Reovirus mutantes y metodos de elaboracion y uso de los mismos
WO2009052617A1 (fr) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Régime de traitement pour des troubles prolifératifs
CN103169973A (zh) * 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy

Also Published As

Publication number Publication date
ZA201008017B (en) 2012-02-29
WO2009143611A1 (fr) 2009-12-03
US20130243732A1 (en) 2013-09-19
EP2296679A1 (fr) 2011-03-23
IL208380A0 (en) 2010-12-30
EP2296679A4 (fr) 2012-03-21
AU2009253683B2 (en) 2015-08-20
AU2009253683A1 (en) 2009-12-03
IL208380A (en) 2013-11-28
CA2723587A1 (fr) 2009-12-03
MX2010012857A (es) 2010-12-20
CN102065873A (zh) 2011-05-18
CA2723587C (fr) 2017-09-26
US8470312B2 (en) 2013-06-25
JP2011520994A (ja) 2011-07-21
US20110070200A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
US11246930B2 (en) Reoviruses having modified sequences
TW200951143A (en) Modulating interstitial pressure and oncolytic viral delivery and distribution
CN104195115A (zh) 突变的呼肠孤病毒及其制备和使用方法
JP5241059B2 (ja) 腫瘍崩壊ウイルスを使用して疼痛を軽減するための方法
TW200950777A (en) Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
Dueker Understanding Mucosal and Systemic Immunity for Targeted Immunization
JP2023526091A (ja) がんの予防または治療用薬学的組成物
EP4262835A1 (fr) Utilisation d'un birnavirus seul ou en polythérapie pour le traitement d'un cancer
WO2015017915A1 (fr) Procédés de traitement de sujets naïfs pour les taxanes présentant des tumeurs primaires ou un cancer métastasique
JP2006524192A (ja) 禽用ワクチンの効能を改善できるワクチン増強因子（ｖａｆ）
Csatary et al. PROMISING NEWCASTLE DISEASE VIRUS (NDV) THERAPY IN HUMAN HIGH GRADE GLIOMAS